Genzyme reports positive data from 5-year alemtuzumab Phase 2 study in MS
Links shared publicly online about this topic.
- 364total visits
Genzyme reports positive data from 5-year alemtuzumab Phase 2 study in MS
Genzyme Corp., a subsidiary of sanofi-aventis Group, today reported additional five-year patient data from its completed Phase 2 multiple sclerosis (MS) trial showing that nearly two-thirds of alemtuzumab treated patients remained free of clinically-active disease as much as four years after most patients received their last course of the investigational drug.
View full resource at news-medical.net
Tags: Multiple Sclerosis, Disease and Condition, Drug, Phase 2 Clinical Trial, Sanofi-Aventis, Genzyme, disease
Most Recently Shared on April 15, 2011 at 9:51 am By:
Genzyme reports positive data from 5-year alemtuzumab Phase 2 study in MS: Genzyme Corp., a subsidiary of sanofi... http://bit.ly/f0aQFV
Advertisement
